Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01608711 · ClinicalTrials.gov registry record · Phase 2
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
A Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, sponsored by Agensys.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT01608711 is a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal that has completed, run by Agensys. The registered enrollment target is 2 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01608711, a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, has completed, sponsored by Agensys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.
Conditions Studied
Interventions
- BIOLOGICAL AGS-1C4D4
- BIOLOGICAL gemcitabine
Study Locations (2)
Wisconsin
- Site US116 - Madison
Other
- Site CA00203 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-08-07 |
| Est. Completion | 2015-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01608711
The ClinicalTrials.gov registry entry for NCT01608711 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Agensys, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which AGS-1C4D4 is the first listed.
NCT01608711 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Wisconsin, Other.
Frequently Asked Questions
What is clinical trial NCT01608711 about?
NCT01608711 is a clinical study titled "A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002". The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.
What is the current status of trial NCT01608711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-08-07. Estimated completion is 2015-11-16.
What conditions does trial NCT01608711 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease.
What interventions are being tested in trial NCT01608711?
The interventions under investigation include: AGS-1C4D4 (BIOLOGICAL), gemcitabine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01608711?
This trial is sponsored by Agensys, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01608711 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.